Antitumor vaccination with gene-transduced tumor cells expressing a fusion protein RM4/IFN-τ

Cancer Biotherapy and Radiopharmaceuticals

Volumn 12, Issue 2, 1997, Pages 123-130

  Xiang, Jim ^a,b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b Saskatoon Cancer Center   (Canada)

Author keywords

Antitumor vaccination; Engineered tumor cells; Recombinant fusion protein

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CHROMIUM; HYBRID PROTEIN; TUMOR VACCINE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENICITY; CELL LINE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE THERAPY; GENETIC TRANSDUCTION; LYMPHOCYTE DEPLETION; MEMORY CELL; MOUSE; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; VACCINATION;

EID: 0030870460     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1997.12.123     Document Type: Article

References (27)

1. De Maeyer E and De Maeyer-Guignard J. "Interferons and other regulatory cytokines" John Wiley and Sons, Inc., New York, New York, USA, 1988.
2. Ros F, Cochet M and Fellous M. Interferon and major histocompatibility complex genes: A model to analyze eukaryotic gene regulation. In: Interferon-τ (ed. Gresser, I.). London: Academic Press Inc., pp47-87, 1986.
3. Schwartz R, Momburg F, Moldenhauer G, Dorken B and Schirrmacher V. Induction of HLA class II antigen expression on human carcinoma cell lines by IFN-τ; Int J Cancer 1985;35:245-252.
4. Fady C, Gardner A, Gera J and Lichtenstein A. Interferon-induced increase in sensitivity of ovarian cancer targets to lysis by lymphokine-activated killer cells: Selective effects on HER2/neu expressing cells. Cancer Res 1992;52:764-769.
5. Tanaka K, Isselbacher K, Khoury G and Jay G. Reversal of oncogenesis by the expression of a major histocompatibility complex class I gene. Science 1985;228:26-29.
6. Greiner J, Guadagni F, Noguchi P, Pestka S, Colcher D, Fisher P and Schlom J. Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesions in vivo. Science 1987;235:895-898.
7. Kantor J, Tran R, Greiner J, Pestka S, Fisher P, Shively J and Schlom J. Modulation of carcinoembryonic antigen messenger RNA levels in human colon carcinoma cells by recombinant human τ-interferon Cancer Res 1989;49:2651-2655.
8. Adams D and Hamilyon T. Molecular transduction mechanisms by which IFN-gamma and other signals regulate macrophage development. Immunol Rev 1987;97:5-19.
9. Weigent D, Stanton J and Johnson H. Recombinant gamma interferon. Biochem Biophys Res Commun 1983;111:525-529.
10. Sone S, Utsugi T and Ogura T. Differential effects of recombinant interferon alpha, beta and gamma on induction of human lymphokine-activated killer activity. J Natl Cancer lnst 1988;80:425-431.
11. Kurzrock R. Interferon gamma In "Cytokine therapy" (eds, D W Galvani and J C Cawley), pp131-151, Cambridge University, Cambridge, England, 1992
12. FitzGerald D, Willingham M, Cardarelli C, Hamada H, Tsuruo T, Gottesman M and Pastan I. A monoclonal antibody-pseudomonas toxin conjugate that specifically kills multidrug-resistant cells PNAS 1987;84:4288-4292.
13. Harven E, Fradet Y, Connolly J, Hana W, He S, Wang Y, Choi B, McGroarty R, Bootsma G, Tilup A and Christensen H Antibody drug carrier for immunotherapy of superficial bladder cancer. Ultrastructural studies Cancer Res 1992,52:3131-3137.
14. Schmidberger H, Buchsbaum D, Blazar B, Everson P and Vallera D. Radiotherapy in mice with Yetrium-90-labeled anti-Ly1 monoclonal antibody: therapy of the T cell lymphoma EL4. Cancer Res 1991;51:1883-1890.
15. Hoogenboom H, Volckaert G and Raus J. Construction and expression of antibody-tumor necrosis factor fusion protein Mol Immunol 1991;28:1027-1037
16. Xiang J, Moyana T, Kaira J, Hamilton T and Qi Y. Construction and characterization of a high-affinity chimeric anti-colorectal carcinoma antibody ccM4. Mol Biother 1992;4:174-182.
17. Xiang J, Qi Y, Chen Y and Moyana T. Targeting gamma interferon to tumor cells by a genetically engineered bifunctional fusion protein RM4/IFN-τ. Hum Antibod Hybridomas 1996;7:1-7.
18. Qi Y, Chen Y and Xiang J. Mouse myeloma cell line secreting fusion protein RM4/IFN-τ elicits antitumor CD8 MHC class I-restricted T cells that are cytolytic in vitro and tumoricidal in vivo J Interferon & Cytokine Res 1996;16:771-776.
19. Qi Y, Moyana T, Chen Y and Xiang J. Characterization of antitumor immunity derived from the inoculation of myeloma cells secreting the fusion protein RM4/IFN-τ. Hum Antibod Hybridomas 1996;7:21-26
20. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific and long-term antitumor immunity. PNAS 1993;90:3539.
21. Norusis M. Statistical Package of Social Science for Windows. Base System User's Guide. Release 6.0, SPSS Inc., Chicago, IL, 1993.
22. Novelli F, Giovarelli M, Reber-Liske R, et al. Blockade of physiologically secreted interferon-gamma inhibits human T-lymphocyte and NK activation. J Immunol 1991;147:1145-1152.
23. Finkelman F and Urban J. Cytokines: making the right choice Parasitol Today 1992;8:311-314.
24. Golumbeck P, Lazenby A, Levitsky H, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin 4. Science 1991;254:719-721.
25. Katsanis E, Orchard P, Bausero M, et al. IL-2 gene transfer into murine neuroblastoma decreases tumorigenicity and enhances systemic immunity causing regression of preestablished retroperitoneal tumors. J Immunotherapy 1994;15:81-90.
26. Allione A, Consalvo M, Nanni P, et al. Immunization and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with IL-2, IL-4, IL-6, IL-7, IL-10, TNF, GMCSF and IFN gene or admixed with conventional adjuvants. Cancer Res 1994;54:6022-6026.
27. Cavallo F, Di Pierro F, Giovarelli M, et al. Protective and curative potential of vaccination with IL-2 gene-transfected cells from a spontaneous mouse mammary adenocarcinoma. Cancer Res 1993;53:5067-5070.